Targeted Alpha Therapy with 213Bi

Title: Targeted Alpha Therapy with 213Bi

Volume: 4 Issue: 4

Author(s): Alfred Morgenstern, Frank Bruchertseifer and Christos Apostolidis

Affiliation:

Keywords: Targeted alpha therapy, alpha emitter, actinium-225, bismuth-213, preclinical studies, clinical application, Alpha emitting radionuclides, RADIONUCLIDE GENERATORS, radiolabeled peptide, SPECT

Abstract: The potential of targeted therapy with the alpha emitter 213Bi has been successfully demonstrated in a large number of preclinical studies and several clinical trials have provided evidence for its feasibility, safety and therapeutic efficacy. This review describes methods for the production of 225Ac and 225Ac/213Bi radionuclide generators, gives an overview of selected preclinical studies and summarizes the current clinical experience with 213Bi.

Cite this article as:

Morgenstern Alfred, Bruchertseifer Frank and Apostolidis Christos, Targeted Alpha Therapy with 213Bi, Current Radiopharmaceuticals 2011; 4 (4) . https://dx.doi.org/10.2174/1874471011104040295